Overview: The FY 2022 fiscal year bill provides a total program level of $6.3 billion. This is an increase of $200.7 million.

Budget Authority: The bill provides $3.4 billion in budget authority. This is a net increase of $81.2 million over FY 2021. Within the total program level, there is a $102.2 million increase for medical product, food safety, and crosscutting activities as well as a decrease of $20.0 million in no-year funding for the 21st Century Cures Innovation Account and a decrease of $1.0 million1 from the one-time increase for Seafood Safety Studies (GP Sec. 765) in FY 2021.

User Fees: The bill provides $2.9 billion for user fees.

Key Increases:

Infrastructure – increase of $2.4 million for FDA Infrastructure below compared to FY 2021:
  - +$0.8 million for FDA White Oak Complex
  - +$2.5 million for Other Rent and Rent Related
  - -$0.8 million decrease for GSA Rental Payments

Crosscutting – increases of $41.3 million for Crosscutting activities below compared to FY 2021:
  - +$3.0 million for Data Modernization Enterprise-Wide Technology and Data
  - +$10.0 million for Inspections
  - +$17.9 million for Pay Costs
  - +$4.7 million for the Office of Minority Health and Health Equity
  - +$1.5 million for Laboratory Safety
  - +$2.2 million for Office of the Chief Counsel
  - +$2.0 million for Essential Services

Food Safety – increases of $29.5 million for Food Safety activities below compared to FY 2021
  - +$9.0 million for New Era of Smarter Food Safety
  - +$11.0 million for Maternal and Infant Health and Nutrition
  - +$7.0 million for Emerging Chemical and Toxicological Issues
  - +$1.5 million for Standards of Identity
  - +$1.0 million for Animal Feed Ingredient Reviews

Medical Product Safety – increases of $29.0 million for Medical Product Safety activities compared to FY 2021
  - +$5.0 million for Shortages & Supply Chain
  - +$1.5 million for Animal Medical Product Supply Chain
  - +$8.0 million for Advancing the Goal of Ending the Opioid Crisis
  - +$3.0 million for Predictive Toxicology Roadmap
  - +$1.0 million for Data Modernization Medical Product Safety
  - +$2.5 million for Orphan Product Grants
  - +$1.0 million for Rare Cancer
  - +$5.0 million for Foreign Inspection Pilot

1 Included in General Provisions Section 765; the total not included in Title VI of Division A of the PL 113-260.
• $1.5 million for Rare Diseases
• $0.5 million for BioFilm Regulatory Research

**Required Transfer:** The bill directs FDA to transfer $1.5 million from FDA Headquarters to HHS' Office of Inspector General to support oversight of FDA's expanded authorities.